![]() |
市場調査レポート
商品コード
1629913
エリスロポエチン製剤の世界市場 - 2025年~2032年Global Erythropoietin Drugs Market - 2025-2032 |
||||||
カスタマイズ可能
適宜更新あり
|
エリスロポエチン製剤の世界市場 - 2025年~2032年 |
出版日: 2024年12月30日
発行: DataM Intelligence
ページ情報: 英文 176 Pages
納期: 即日から翌営業日
|
エリスロポエチン製剤の世界市場は2024年に107億7,000万米ドルに達し、そして2032年には145億9,000万米ドルに達すると予測され、予測期間2025年のCAGRは7.9%です。
エリスロポエチン製剤は、天然に存在するホルモンであるエリスロポエチン(EPO)の合成型であり、主に腎臓で産生されます。EPOは、骨髄における赤血球産生、特に血液中の低酸素レベルに対応する赤血球産生の調節において重要な役割を果たしています。これらの薬剤は主に貧血の治療に使用され、特に慢性腎臓病を患っている患者、がんの化学療法を受けている患者、または体内で十分な赤血球を産生する能力を妨げているその他の疾患を持つ患者に使用されます。
赤血球前駆細胞の分化と増殖を刺激することにより、エリスロポエチン製剤は赤血球数を効果的に増加させ、疲労や脱力感などの貧血に伴う症状を緩和するのに役立ちます。
促進要因と抑制要因
貧血の有病率の増加
特に慢性腎臓病(CKD)やがんなどの慢性疾患によって引き起こされる貧血の有病率の増加が、エリスロポエチン製剤市場の成長を大きく後押ししています。腎機能低下は赤血球形成に不可欠なエリスロポエチンの産生低下につながるため、貧血はCKD患者によく見られる合併症です。例えば、2024年の米国国立衛生研究所の報告によると、CKDの貧血は通常、GFRが60mL/分/1.73m2を下回ると発症し、ステージ3のCKD患者の最大20%が貧血を示します。透析依存となった患者の少なくとも90%が最終的に貧血を発症します。
人口の高齢化、食生活の変化、CKDのような疾患の有病率の増加などの要因により、世界的に貧血患者が増加しており、エリスロポエチンをベースとした薬剤のような効果的な治療に対するニーズが高まっています。
さらに、がん治療、特に化学療法は、骨髄機能に影響を与えるため、しばしば貧血を引き起こします。CKDやがんと診断される患者数が世界的に増加し続ける中、赤血球産生を促進し貧血に伴う症状を緩和するために重要なエリスロポエチン製剤の需要が増加しています。
エリスロポエチン製剤に関連する副作用と安全性の懸念
エリスロポエチン製剤に関連する副作用と安全性の懸念がエリスロポエチン製剤市場の妨げとなっています。EPO製剤は貧血治療に有効であるが、使い過ぎると深刻な副作用を引き起こす可能性があります。これには、高血圧、心臓発作や脳卒中などの心血管系イベント、血栓塞栓イベントが含まれます。場合によっては、EPO製剤が血栓のリスクを高めたり、基礎にある心臓の状態を悪化させたりして、深刻な健康合併症を引き起こすこともあります。
The global erythropoietin drugs market reached US$ 10.77 billion in 2024 and is expected to reach US$ 14.59 billion by 2032, growing at a CAGR of 7.9% during the forecast period 2025-2032.
Erythropoietin drugs are synthetic forms of the naturally occurring hormone erythropoietin (EPO), which is primarily produced by the kidneys. EPO plays a crucial role in regulating red blood cell production in the bone marrow, particularly in response to low oxygen levels in the blood. These drugs are primarily employed to treat anemia, especially in patients suffering from chronic kidney disease, those undergoing chemotherapy for cancer, or individuals with other conditions that hinder the body's ability to produce adequate red blood cells.
By stimulating the differentiation and proliferation of erythroid progenitor cells, erythropoietin drugs effectively increase red blood cell counts, which helps alleviate symptoms associated with anemia, such as fatigue and weakness.
Market Dynamics: Drivers & Restraints
Increasing prevalence of anemia
The increasing prevalence of anemia, particularly driven by chronic diseases such as chronic kidney disease (CKD) and cancer, is significantly propelling the growth of the erythropoietin drugs market. Anemia is a common complication in patients with CKD, as impaired kidney function leads to reduced production of erythropoietin, which is essential for red blood cell formation. For instance, according to the report by the National Institute of Health in 2024, Anemia of CKD typically develops when the GFR falls below 60 mL/min/1.73 m2, with up to 20% of patients at stage 3 CKD demonstrating anemia. At least 90% of patients who become dialysis-dependent will eventually develop anemia.
With the rising global anemia patients, driven by factors like aging populations, dietary changes, and the growing prevalence of diseases such as CKD, there is a growing need for effective treatments like erythropoietin-based drugs.
Additionally, cancer treatments, especially chemotherapy, often result in anemia due to their impact on bone marrow function. As the number of individuals diagnosed with CKD and cancer continues to rise globally, the demand for erythropoietin drugs increases, which are critical for stimulating red blood cell production and alleviating symptoms associated with anemia.
Adverse effects and safety concerns associated with erythropoietin drugs
The adverse effects associated with the erythropoietin drugs and the safety concerns associated are hindering the erythropoietin drugs market. While EPO drugs are effective in treating anemia, their overuse can lead to serious side effects. These include hypertension, cardiovascular events such as heart attacks or strokes, and thromboembolic events. In some cases, EPO drugs can increase the risk of blood clots or worsen underlying heart conditions, leading to severe health complications.
The global erythropoietin drugs market is segmented based on drug type, indication, route of administration, distribution channel, end-user, and region.
Epoetin alfa segment is expected to dominate the global erythropoietin drugs market share
The epoetin alfa segment is anticipated to lead the erythropoietin (EPO) drugs market due to its proven efficacy, widespread use, and cost-effectiveness. Epoetin alfa is primarily prescribed to treat anemia related to chronic kidney disease (CKD), chemotherapy, and other conditions. Its long-standing track of safety and effectiveness makes it a preferred choice for healthcare professionals in managing anemia.
The extensive clinical experience with epoetin alfa has resulted in its strong market presence, particularly in regions with well-developed healthcare systems. Additionally, the availability of both branded and biosimilar versions of epoetin alfa is allowing it to an accessible to a broader patient population.
Biosimilars, being more affordable alternatives to the original drug, have gained popularity and helped expand the reach of epoetin alfa therapies. The combination of these affordable biosimilars and the increasing prevalence of anemia, especially in conditions like CKD, is expected to further strengthen the dominance of the epoetin alfa segment in the EPO drugs market.
North America is expected to hold a significant position in the global erythropoietin drugs market share
North America is expected to hold a significant position in the erythropoietin (EPO) drugs market. The region's growth is driven by the incidence of anemia, a robust healthcare system, and ongoing advancements in medical research and treatment options. The region has a significant number of people suffering from chronic diseases such as chronic kidney disease (CKD), cancer, and diabetes, which are major contributors to anemia. For instance, according to the Centers for Disease Control and Prevention in 2024, more than 1 in 7 US adults, about 35.5 million people, or 14% are estimated to have CKD. This incidence is expected to increase the occurrence of anemia. As the prevalence of these conditions rises, the demand for effective treatments like erythropoietin drugs, which stimulate the production of red blood cells to address anemia, continues to grow.
Pharmaceutical companies, especially those located in the U.S. and Canada, are leading the way in the research and development of erythropoietin therapies. The presence of several pharmaceutical companies in the region is leading to the innovation of advanced and more effective drug formulations for managing anemia. For instance, In February 2023, GSK plc received the US Food and Drug Administration (FDA) approval for Jesduvroq (daprodustat), for the once-a-day treatment of anemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis for at least four months.
Jesduvroq is the first innovative medicine for anemia treatment in over 30 years and the only HIF-PHI approved in the US, providing a new oral, convenient option for patients in the US with anemia of CKD on dialysis.
Furthermore, the increasing awareness of anemia and its related conditions, coupled with the demonstrated effectiveness of EPO drugs, is driving greater demand in North America. These combined factors are positioning North America as a major player in the global erythropoietin drugs market.
The major global players in the erythropoietin drugs market include Dr. Reddy's Laboratories Ltd., Otsuka Pharmaceutical Co., Ltd., Johnson & Johnson Services, Inc., Teva Pharmaceutical Industries Ltd., AbbVie Inc., Alkermes, Eli Lilly and Company, Bristol-Myers Squibb Company, Sumitomo Pharma Co., Ltd. and Pfizer Inc. among others.
The Global Erythropoietin Drugs market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.
LIST NOT EXHAUSTIVE